$7.780
-0.069 (-0.89%)收盤時
KMDA 資訊
KMDA 事件
Kamada Launches Two Biosimilars in Israel
Kamada announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products. The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis and pulmonary embolism, as well as for use in certain acute coronary syndrome settings. The launch of the new products is in addition to the company's first two biosimilar products, Bevacizumab-Kamada, a biosimilar to Avastin, and Pegfilgrastim-Kamada, a biosimilar to Neulasta, which were launched in the Israeli market over the last two years. The company expects the commercial availability of at least two additional biosimilar products during 2027. All four biosimilar products were approved and launched as interchangeable with the reference original biologic product. Kamada's existing commercial portfolio of biosimilars is anticipated to generate approximately $4M in sales in 2026, growing to approximately $10M in 2028. By 2030, the company expects this strategic portfolio to include at least 12 marketed products, licensed from 6 different leading international biosimilar companies, to be commercialized in Israel and the Middle East and North Africa region, with the expectation to generate between approximately $20M to $25M in annual revenue. Kamada expects that additional biosimilar products, licensed by Kamada, will be in development or registration phase by 2030, contributing to further meaningful expansion of the portfolio.
Kamada Confirms Sufficient KedRAB Supply for Increased U.S. Demand
Kamada confirmed that it maintains sufficient KedRAB supply and manufacturing capacity to meet increased demand for the product in the United States. The confirmation follows a Health Advisory published by the U.S. Centers for Disease Control and Prevention on September 10, reporting a significant nationwide year-over-year increase in human rabies exposures and the use of rabies post-exposure prophylaxis. In light of this increase in end-user utilization described in the CDC advisory, Kamada confirms it has the inventory and manufacturing capacity to support the continued supply of KedRAB, a human rabies immune globulin developed and manufactured by Kamada, which is one of only two FDA-approved anti-rabies immunoglobulin products indicated for PEP treatment in the U.S. The product is supplied to the U.S. market via the Company's U.S. commercialization partner, Kedrion Biopharma.
Kamada Files to Sell $50M of Ordinary Shares
Kamada files to sell $50M of ordinary shares
Kamada Reiterates 2026 Revenue Guidance of $200M to $205M
The company said, "Kamada is reiterating its 2026 annual financial guidance of total revenues in the range of $200 million to $205 million, and adjusted EBITDA in the range of $50 million to $53 million, representing year-over-year increase of 12% in revenues and 23% in adjusted EBITDA based on mid-point of 2026 annual guidance."
Kamada Reports Q2 Revenue of $54.92M
Reports Q2 revenue $54.92M vs. $44.75M last year. "We continue to execute on our plan delivering record-high operational and financial performance during the first half of 2026, with strong double-digit growth in revenues and adjusted EBITDA for both the six-month and second quarter reporting periods," said Amir London, Kamada's Chief Executive Officer. "The first half of the year was the strongest in Kamada's history with revenues of $100.2 million and adjusted EBITDA of $25.7 million, representing notable 26% margin of revenues. The underlying demand for our products, including KEDRAB in the U.S. market, as well as VARIZIG and HEPAGAM, continues to increase significantly. Based on our first half performance, representing approximately 50% of our annual guidance midpoints, we are reiterating our 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, respectively, representing 12% and 23% growth when comparing 2026 guidance mid-points to 2025 results."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。